287 results on '"Rossi-Bergmann, Bartira"'
Search Results
2. Crosslinked chitosan microparticles as a safe and efficient DNA carrier for intranasal vaccination against cutaneous leishmaniasis
3. Nano and Microstructured Delivery Systems for Current Antileishmanial Drugs
4. Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis
5. Encapsulation in lipid-core nanocapsules improves topical treatment with the potent antileishmanial compound CH8
6. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles
7. Nano and Microstructured Delivery Systems for Current Antileishmanial Drugs
8. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis
9. Synthesis and evaluation of hybrid sulfonamide‐chalcones with potential antileishmanial activity.
10. Intranasal but not subcutaneous vaccination with LaAg allows rapid expansion of protective immunity against cutaneous leishmaniasis
11. Cysteinyl-leukotrienes promote cutaneous Leishmaniasis control
12. Nanomedicines for Cutaneous Leishmaniasis
13. Intralesional uridine-5′-triphosphate (UTP) treatment induced resistance to Leishmania amazonensis infection by boosting Th1 immune responses and reactive oxygen species production
14. In Vivo Safety and Efficacy of Chalcone-Loaded Microparticles with Modified Polymeric Matrix against Cutaneous Leishmaniasis
15. The role of the P2X7 receptor in murine cutaneous leishmaniasis: aspects of inflammation and parasite control
16. Chemical diversity and antileishmanial activity of crude extracts of Laurencia complex (Ceramiales, Rhodophyta) from Brazil
17. Performance of Elastic Liposomes for Topical Treatment of Cutaneous Leishmaniasis
18. Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice
19. Development of Immunological Assays Based on Leishmania donovani Antigen for Diagnosis of Canine Visceral Leishmaniasis and Their Multicenter Evaluation in Brazil and Italy
20. Eugenol derivatives with 1,2,3-triazole moieties: Oral treatment of cutaneous leishmaniasis and a quantitative structure-activity relationship model for their leishmanicidal activity
21. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum
22. Targeting chalcone binding sites in living Leishmania using a reversible fluorogenic benzochalcone probe
23. Protein Prenylation in Trypanosomatids : A New Piggy-Back Medicinal Chemistry Target for the Development of Agents Against Tropical Diseases
24. In Vivo Safety and Efficacy of Chalcone-Loaded Microparticles with Modified Polymeric Matrix against Cutaneous Leishmaniasis.
25. Influence of cultivation conditions, season of collection and extraction method on the content of antileishmanial flavonoids from Kalanchoe pinnata
26. Chalcones identify cTXNPx as a potential antileishmanial drug target
27. Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi.
28. Ivermectin-derived leishmanicidal compounds
29. MPLA and AddaVax® Adjuvants Fail to Promote Intramuscular LaAg Vaccine Protectiveness against Experimental Cutaneous Leishmaniasis
30. Oligopeptidase B-2 from Leishmania amazonensis with an unusual C-terminal extension
31. Oligopeptidase B from Leishmania amazonensis: molecular cloning, gene expression analysis and molecular model
32. Structure–activity relationship of antileishmanials neolignan analogues
33. Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan
34. Antileishmanial Chemotherapy through Clemastine Fumarate Mediated Inhibition of the Leishmania Inositol Phosphorylceramide Synthase
35. Nanoparticles Loaded with a New Thiourea Derivative: Development and In vitro Evaluation Against Leishmania amazonensis
36. Peripheral expression of LACK-mRNA induced by intranasal vaccination with PCI-NEO-LACK defines the protection duration against murine visceral leishmaniasis
37. Synthesis of chalcone analogues with increased antileishmanial activity
38. Intranasal immunization with LACK-DNA promotes protective immunity in hamsters challenged with Leishmania chagasi
39. Effectiveness of the local or oral delivery of the novel naphthopterocarpanquinone LQB-118 against cutaneous leishmaniasis
40. Vitamin D increases killing of intracellular Leishmania amazonensis in vitro independently of macrophage oxidative mechanisms
41. Single-dose treatment for cutaneous leishmaniasis with an easily synthesized chalcone entrapped in polymeric microparticles
42. Leishmanicidal activity of Piper marginatum Jacq. from Santarém-PA against Leishmania amazonensis
43. Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone
44. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis
45. Nanoencapsulated retinoic acid as a safe tolerogenic adjuvant for intranasal vaccination against cutaneous leishmaniasis
46. Dietary Vitamin D3 Deficiency Increases Resistance to Leishmania (Leishmania) amazonensis Infection in Mice
47. The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy
48. Developing an intranasal vaccine against canine visceral leishmaniasis: a study of efficacy in mice
49. Broad Spectrum and Safety of Oral Treatment with a Promising Nitrosylated Chalcone in Murine Leishmaniasis
50. Antileishmanial Chemotherapy through Clemastine Fumarate Mediated Inhibition of the Leishmania Inositol Phosphorylceramide Synthase.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.